Medtech Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Financings In Brief

This article was originally published in The Gray Sheet

Executive Summary

Vital Therapies funds artificial liver development: Start-up raises $28.1 million in a "Series C" private placement to support further development of its ELAD extracorporeal liver assist device, the firm announces Sept. 12. The San Diego company is conducting a pivotal trial of the human cell-based artificial liver in China to support a planned near-term marketing application in that country, "and to provide more safety data for U.S. registration," according to the company. The firm anticipates Chinese approval this year and a U.S. market go-ahead by the end of the decade. ELAD, which is regulated as a biologic by FDA with input from the agency's device center, is intended as a bridge-to-transplant or for potential liver recovery for patients with severe liver failure. Vital Therapies acquired the bedside-use technology in 2003 from VitaGen (1"The Gray Sheet" Oct. 6, 2003, p. 26). The recent financing round was led by Versant Ventures
Advertisement
Advertisement

Related Content

Advertisement
UsernamePublicRestriction

Register

MT025257

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel